figshare
Browse
pone.0298596.s002.docx (13.33 kB)

Overview of the individual studies included in the rivaroxaban post-authorization safety study (PASS) program.

Download (13.33 kB)
journal contribution
posted on 2024-03-07, 18:33 authored by Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M. C. Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez

Overview of the individual studies included in the rivaroxaban post-authorization safety study (PASS) program.

History

Usage metrics

    PLOS ONE

    Categories

    Keywords

    vitamin k antagonistsvitamin k antagonistroutine clinical practicerecent cancer history9 &# 8211time users treatedbleeding ), deatheuropean rivaroxaban post44 737 rivaroxabanxlink "> overallxlink "> cohortsamong rivaroxaban userscrude incidence ratesdecember 2017 ).venous thromboembolism indicationxlink ">rivaroxaban usersvenous thromboembolismincidence ratesdecember 2017vte indicationdecember 2018december 2016december 2011study providesstudy endsecondary preventionsafety profilesafety outcomerenal impairmentjanuary 2012gastrointestinal bleedingcomplement findingsatrial fibrillation

    Licence

    CC BY 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC